Lexaria Bioscience: A Misunderstood Growth Story
During the last week, Lexaria Bioscience (Nasdaq: LEXX) has come under pressure and we believe the pullback has created a great opportunity for investors. The biotech company has been nothing…
Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4
KELOWNA, BC / ACCESSWIRE / February 21, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce additional findings from its human…
Lexaria Bioscience: An Undervalued Growth Story
Earlier this year, we highlighted Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) as an undervalued biotech company and want to provide more information on the story. During the last year,…
CEO Spotlight: Lexaria Bioscience
Today, we are lucky to have Lexaria Bioscience CEO Chris Bunka with us. During the last year, the biotech company has reported a series of positive developments and we are…
Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic Advisor
KELOWNA, BC / ACCESSWIRE / January 23, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce that the former…
Lexaria Bioscience: A Deep Dive
Earlier this year, we published a business opportunity report on Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) and believe the company is flying under the radar. The biotech company operates…
